292 related articles for article (PubMed ID: 26044819)
1. Comparison of high versus low-medium prednisone doses for the treatment of systemic lupus erythematosus patients with high activity at diagnosis.
Ruiz-Arruza I; Barbosa C; Ugarte A; Ruiz-Irastorza G
Autoimmun Rev; 2015 Oct; 14(10):875-9. PubMed ID: 26044819
[TBL] [Abstract][Full Text] [Related]
2. Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus.
Ruiz-Arruza I; Ugarte A; Cabezas-Rodriguez I; Medina JA; Moran MA; Ruiz-Irastorza G
Rheumatology (Oxford); 2014 Aug; 53(8):1470-6. PubMed ID: 24681836
[TBL] [Abstract][Full Text] [Related]
3. Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: An observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts.
Ruiz-Irastorza G; Ugarte A; Saint-Pastou Terrier C; Lazaro E; Iza A; Couzi L; Saenz R; Richez C; Porta S; Blanco P
Autoimmun Rev; 2017 Aug; 16(8):826-832. PubMed ID: 28564619
[TBL] [Abstract][Full Text] [Related]
4. Prolonged remission in SLE is possible by using reduced doses of prednisone: An observational study from the Lupus-Cruces and Lupus-Bordeaux inception cohorts.
Ruiz-Irastorza G; Ruiz-Estevez B; Lazaro E; Ruiz-Arruza I; Duffau P; Martin-Cascon M; Richez C; Ugarte A; Blanco P
Autoimmun Rev; 2019 Sep; 18(9):102359. PubMed ID: 31323362
[TBL] [Abstract][Full Text] [Related]
5. Restrictive Use of Oral Glucocorticoids in Systemic Lupus Erythematosus and Prevention of Damage Without Worsening Long-Term Disease Control: An Observational Study.
Ruiz-Arruza I; Lozano J; Cabezas-Rodriguez I; Medina JA; Ugarte A; Erdozain JG; Ruiz-Irastorza G
Arthritis Care Res (Hoboken); 2018 Apr; 70(4):582-591. PubMed ID: 28704598
[TBL] [Abstract][Full Text] [Related]
6. Prednisone in lupus nephritis: how much is enough?
Ruiz-Irastorza G; Danza A; Perales I; Villar I; Garcia M; Delgado S; Khamashta M
Autoimmun Rev; 2014 Feb; 13(2):206-14. PubMed ID: 24189280
[TBL] [Abstract][Full Text] [Related]
7. Infections in newly diagnosed Spanish patients with systemic lupus erythematosus: data from the RELES cohort.
González-Echavarri C; Capdevila O; Espinosa G; Suárez S; Marín-Ballvé A; González-León R; Rodríguez-Carballeira M; Fonseca-Aizpuru E; Pinilla B; Pallarés L; Ruiz-Irastorza G;
Lupus; 2018 Dec; 27(14):2253-2261. PubMed ID: 30451641
[TBL] [Abstract][Full Text] [Related]
8. Glucocorticoids and antimalarials in systemic lupus erythematosus: an update and future directions.
Ugarte A; Danza A; Ruiz-Irastorza G
Curr Opin Rheumatol; 2018 Sep; 30(5):482-489. PubMed ID: 29870497
[TBL] [Abstract][Full Text] [Related]
9. Patterns of drug therapy in newly diagnosed Spanish patients with systemic lupus erythematosus.
Ruiz-Irastorza G; García M; Espinosa G; Cabezas-Rodríguez I; Mitjavila F; González-León R; Sopeña B; Perales I; Pinilla B; Rodríguez-Carballeira M; López-Dupla JM; Callejas JL; Castro A; Tolosa C; Sánchez-García ME; Pérez-Conesa M; Navarrete-Navarrete N; Rodríguez AP; Herranz MT; Pallarés L;
Clin Exp Rheumatol; 2016; 34(3):466-72. PubMed ID: 26940538
[TBL] [Abstract][Full Text] [Related]
10. The administration of low doses of rituximab followed by hydroxychloroquine, prednisone and low doses of mycophenolate mofetil is an effective therapy in Latin American patients with active systemic lupus erythematosus.
Galarza-Maldonado C; Kourilovitch MR; Molineros JE; Cardiel MH; Zurita L; Soroka NF; Yagur VY; Doukh N; Cervera R
Autoimmun Rev; 2010 Dec; 10(2):108-11. PubMed ID: 20804861
[TBL] [Abstract][Full Text] [Related]
11. Seventy years after Hench's Nobel prize: revisiting the use of glucocorticoids in systemic lupus erythematosus.
Ruiz-Irastorza G; Ugarte A; Ruiz-Arruza I; Khamashta M
Lupus; 2020 Sep; 29(10):1155-1167. PubMed ID: 32539657
[TBL] [Abstract][Full Text] [Related]
12. Factors predictive of serious infections over time in systemic lupus erythematosus patients: data from a multi-ethnic, multi-national, Latin American lupus cohort.
Pimentel-Quiroz VR; Ugarte-Gil MF; Harvey GB; Wojdyla D; Pons-Estel GJ; Quintana R; Esposto A; García MA; Catoggio LJ; Cardiel MH; Barile LA; Amigo MC; Sato EI; Bonfa E; Borba E; Lavras Costallat LT; Neira OJ; Massardo L; Guibert-Toledano M; Chacón-Díaz R; Alarcón GS; Pons-Estel BA
Lupus; 2019 Aug; 28(9):1101-1110. PubMed ID: 31291843
[TBL] [Abstract][Full Text] [Related]
13. Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study.
Apostolopoulos D; Kandane-Rathnayake R; Louthrenoo W; Luo SF; Wu YJ; Lateef A; Golder V; Sockalingam S; Navarra S; Zamora L; Hamijoyo L; Katsumata Y; Harigai M; Chan M; O'Neill S; Goldblatt F; Lau CS; Li ZG; Hoi A; Nikpour M; Morand E;
Lancet Rheumatol; 2020 Jan; 2(1):e24-e30. PubMed ID: 38258272
[TBL] [Abstract][Full Text] [Related]
14. Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosus.
Tsang-A-Sjoe MW; Bultink IE; Heslinga M; Voskuyl AE
Rheumatology (Oxford); 2017 Jan; 56(1):121-128. PubMed ID: 27803306
[TBL] [Abstract][Full Text] [Related]
15. Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity.
Ugarte A; Porta S; Ríos R; Martinez-Zapico A; Ortego-Centeno N; Agesta N; Ruiz-Irastorza G
Lupus; 2018 Sep; 27(10):1718-1722. PubMed ID: 29635998
[TBL] [Abstract][Full Text] [Related]
16. Impact of systemic lupus erythematosus disease activity, hydroxychloroquine and NSAID on the risk of subsequent organ system damage and death: analysis in a single US medical centre.
Hill DD; Eudy AM; Egger PJ; Fu Q; Petri MA
Lupus Sci Med; 2021 Apr; 8(1):. PubMed ID: 33832976
[TBL] [Abstract][Full Text] [Related]
17. Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL).
Ugarte-Gil MF; Wojdyla D; Pons-Estel GJ; Catoggio LJ; Drenkard C; Sarano J; Berbotto GA; Borba EF; Sato EI; Tavares Brenol JC; Uribe O; Ramirez Gómez LA; Guibert-Toledano M; Massardo L; Cardiel MH; Silveira LH; Chacón-Diaz R; Alarcón GS; Pons-Estel BA;
Ann Rheum Dis; 2017 Dec; 76(12):2071-2074. PubMed ID: 28939626
[TBL] [Abstract][Full Text] [Related]
18. Identifying a Response for the Systemic Lupus Erythematosus Disease Activity 2000 Glucocorticoid Index.
Touma Z; Gladman DD; Zandy M; Su J; Anderson N; Urowitz MB
Arthritis Care Res (Hoboken); 2021 Sep; 73(9):1243-1249. PubMed ID: 32433815
[TBL] [Abstract][Full Text] [Related]
19. First month prednisone dose predicts prednisone burden during the following 11 months: an observational study from the RELES cohort.
Ruiz-Irastorza G; Garcia M; Espinosa G; Caminal L; Mitjavila F; González-León R; Sopeña B; Canora J; Villalba MV; Rodríguez-Carballeira M; López-Dupla JM; Callejas JL; Castro A; Tolosa C; Sánchez-García ME; Pérez-Conesa M; Navarrete-Navarrete N; Rodríguez AP; Herranz MT; Pallarés L
Lupus Sci Med; 2016; 3(1):e000153. PubMed ID: 27547439
[TBL] [Abstract][Full Text] [Related]
20. [Methylprednisolone and cyclophosphamide pulse therapy of severe systemic lupus erythematosus in children].
Hu J; Li CW; Zhang X; Pi SH; Zhao JS; Chen XY; Liu Y
Zhonghua Er Ke Za Zhi; 2003 Jun; 41(6):430-4. PubMed ID: 14748998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
